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Placental transfer of maternal IgG antibodies to the fetus is an important mechanism that provides protection to the infant while
his/her humoral response is ineﬃcient. IgG is the only antibody class that signiﬁcantly crosses the human placenta. This crossing
is mediated by FcRn expressed on syncytiotrophoblast cells. There is evidence that IgG transfer depends on the following: (i)
maternal levels of total IgG and speciﬁc antibodies, (ii) gestational age, (iii) placental integrity, (iv) IgG subclass, and (v) nature of
antigen, being more intense for thymus-dependent ones. These features represent the basis for maternal immunization strategies
aimed at protecting newborns against neonatal and infantile infectious diseases. In some situations, such as mothers with primary
immunodeﬁciencies, exogenous IgG acquired by intravenous immunoglobulin therapy crosses the placenta in similar patterns to
endogenous immunoglobulins and may also protect the oﬀspring from infections in early life. Inversely, harmful autoantibodies
may cross the placenta and cause transitory autoimmune disease in the neonate.
1.Introduction
Anti-infectious fetal protection is provided by several factors
acting together. The uterine cavity contains innate immune
detection and eﬀector systems that maintain sterility, detect
infection and, under conditions of substantial microbial
invasion, induce expression of mediators that could accel-
erate lung maturation and induce a preterm labor to deliv-
er the fetus from a threatening environment [1]. The vaginal
tract, which is normally colonized with multiple microor-
ganisms, is separated from the normally sterile intrauterine
compartment by the cervical plug, which contains sev-
eral antimicrobial proteins and peptides (APPs), including
lactoferrin and α-defensins. Inside the uterine cavity, the
amniotic ﬂuid contains acute phase proteins, such as sol-
uble CD14 and lipopolysaccharide- (LPS-) binding protein
(LBP), which modulates the endotoxic activity of LPS
and cationic membrane-active APPs, such as lactoferrin,
bactericidal/permeability-increasing protein, histones, and
defensins [2]. In preterm labor, increased concentrations of
group II phospholipase A2 are found, and this enzyme has
been associated with a remarkable potency against Gram-
positive bacteria [3, 4].
At birth, the neonate presents an increased susceptibility
to infectious agents due to functional immaturity of his/her
immune system. Some functions are particularly immature,
whereas other aspects are functional at birth even in ex-
tremely preterm newborn infants. Neutrophils have a small
storage pool at birth, and this cell lineage is less responsive
to chemoattractants than later in development. Mono-
cytes/macrophages are reported to be functionally adequate
but have limitations in chemotactic responsiveness. Infant
blood monocytes produce less IFN-α,I F N - γ, and IL-12
subunit p70 (IL-12 p70) than cells obtained from adults.
However, production of these cytokines rapidly increases
between birth and 1 or 2 years of age. In contrast, infant cells2 Clinical and Developmental Immunology
show a greater capacity to produce IL-10 and to induce IL-
17-producing helper T cells (Th17 cells) in response to Toll-
like receptor (TLR) stimulation by producing IL-6 and IL-
23 [2]. Furthermore, individual infant cells are less able than
adult cells to produce multiple cytokines simultaneously in
response to TLR agonists; that is, infant cells are less pol-
yfunctional [5]. The predominance of a Th17-like pattern
combined with considerable IL-10 production may contrib-
ute to diminished T helper type 1 (Th1) responses, resulting
ingreatersusceptibilitytointracellularinfectionsanddimin-
ished vaccine responses during infancy [6].
Neonatal T CD4+ cells present an intrinsic immaturity
with a diminished capacity to generate memory cells and
reduced Th1 eﬀector functions such as the production of
less IFN-γ and lower CD40L expression. These deﬁciencies
seem mainly to be related to the fact that the cells are still
naive, having met few antigens [7]. Thymic recent emigrants
(TRECs), which are T cells recently migrated from the
thymus, are present in a large proportion in the periphery
of human infants, and these TRECs are impaired in their
acquisition of Th1 function [8]. CD4+ T cell responses, but
not CD8+ T cell responses, develop more slowly in infants
than in adults after primary infection with cytomegalovirus
or herpes simplex virus [9]. In addition, responses to some
vaccines, such as vaccines for hepatitis B virus and oral
poliovirus vaccine, result in less Th1 activity and a bias
t o w a r dT h 2f u n c t i o n[ 10]. The ability of proinﬂammatory
cytokines to induce spontaneous abortion is likely to be an
important reason for the strong bias of the maternal and
fetal immune systems of multiple mammalian species to-
wards Th2-cell-polarizing cytokines [1, 11]. The Th2 locus
is hypomethylated in both human and mouse infants, con-
tributing to the expression of these cytokine genes, which
corresponds to the propensity for Th2-polarizing cytokine
responses in infants [12, 13]. Thus, infants have a dominant
anti-inﬂammatory cytokine proﬁle that seems to be induced
during fetal life [7]. It has been demonstrated that in the in
utero environment, CD4+CD25hiFoxp3+ regulatory T cells
dominate the fetal circulation, suppressing reactivity to non-
inherited maternal antigens [14] and possibly promoting a
generally suppressive environment.
Regarding neonatal antibody responses, several studies
have shown a delayed onset, lower peak levels, a shorter
duration,diﬀerencesinthedistributionofIgGisotypes(with
infants showing lower IgG2 than adults), and lower aﬃnity
and reduced heterogeneity. Antibody responses to thymus-
independent type 2 antigens (including bacterial polysac-
charides) are also deﬁcient [15] .T h e r ei sn ot r a n s p l a c e n t a l
transfer of complement system elements, and neonates have
relatively low levels of some components [16]. Furthermore,
neonatal and infantile B cells have low expression of CD21
(complement receptor 2), which explains the inadequate re-
sponse to polysaccharides [17]. Interestingly, the increase in
CD21 levels that occurs during development coincides with
the response to polysaccharides [18].
Considering that after exposure to each new microbe
it takes time to develop each speciﬁc protective immune
response, the placental transfer of maternal immunoglob-
ulins to the fetus is a speciﬁc adaptative mechanism that,
to some extent, minimizes the deﬁciencies in antibody pro-
ductionandconfersshort-termpassiveimmunity.Moreover,
additional immune response support is given by the mother
through breast milk, which contains functional nutrients
and IgA antibodies that provide eﬃcient protection directly
after birth by preventing adherence of infectious agents on
the mucosal membranes and ultimately their entrance into
tissues.
2. IgG Placental Transfer IsMediatedby FcRn
In humans, substances that pass from maternal blood to
fetal blood must traverse the histological barrier, which
consists of two cell layers: the multinucleated syncytiotro-
phoblasts (STBs) and endothelial cells of the fetal capillaries.
Furthermore, ﬁbroblasts and Hofbauer cells (i.e., placental
macrophages) are found in the villous stroma and are pre-
sumably involved in the binding and trapping of immune
complexes [19].
Althoughthisbarrierseparatesthebloodinmaternaland
fetal circulation, it is not a simple physical barrier. A wide
range of substances, including nutrients and solutes, are efﬁ-
ciently transferred actively or passively through the placenta
to the fetus, and this mechanism is essential for normal fetal
growth and development. Most low molecular mass com-
pounds(<500Da)simplydiﬀusethroughtheplacentaltissue
interposed between the maternal and fetal circulation. Some
low molecular weight substances, such as ions and amino
acids, show unidirectional transfer across the placenta. Sub-
stances of very high molecular weight do not usually traverse
the placenta, but there are a few exceptions, such as immu-
noglobulin G (IgG), which has a molecular mass of approx-
imately 160kDa.
Of the ﬁve antibody classes, only signiﬁcant amounts of
IgG are transferred across the placenta. On the basis of the
observationthatwholeIgGmoleculesorFcfragmentsofIgG
pass into the fetal circulation more readily than F(ab )2
fragments [20], it was hypothesized that IgG Fc receptors
(FcγRs) on placental cells may be involved in IgG transfer
across placenta. Later, it was established that this speciﬁc
transport of IgG is carried out by the neonatal Fc receptor
(FcRn) [21, 22]. This has been demonstrated unequivocally
in ex vivo perfused placenta by comparing the transport of
a recombinant, humanized IgG1 antibody with that of a
mutated variant that does not bind to FcRn [23]. FcRn is
composed of an integral membrane glycoprotein with an
apparent molecular weight of 40–45kDa for the α-chain,
which is noncovalently associated with β2-microglobulin
(β2m)[24]. Thus, while the major ligands of FcRn are IgG
and albumin, FcRn is most closely structurally related to
major histocompatibility complex (MHC) class I molecules,
with which it shares 22%–29% sequence homology. In con-
trast to other Fcγ-receptors, FcRn exhibits a characteristic
pH-dependency of IgG binding, demonstrating a high afﬁn-
ity for IgG at pH 6.0, but 100-times lower aﬃnity at phys-
iological pH (7.4) [25]. Thus, FcRn is unable to bind IgG at
the apical side of STB facing the maternal blood.
It is, therefore, assumed that IgG present in high concen-
trations in the maternal circulation (10–20mg/mL) is takenClinical and Developmental Immunology 3
Figure 1: IgG transfer from the mother to the fetus occurs
during pregnancy across the syncytiotrophoblasts of the placenta.
Syncytiotrophoblasts are bathed in maternal blood and internalize
maternal IgG in endosomes. FcRn is expressed on the internal
surfaces of the endosome. Upon acidiﬁcation in the endosome,
maternal IgG bound to FcRn is protected from degradation by
lysosomal enzymes and then is transcytosed. The endosomes fuse
with the membrane on the fetal side of the syncytiotrophoblast,
where the physiological pH promotes the dissociation of IgG from
FcRntothefetalcirculation.HighlevelsofIgGantibodiescauseIgG
degradation due to the saturation of FcRn receptors.
up by ﬂuid-phase endocytosis by STB and then binds to the
FcRn in the acidic environment of endosomes [26]. Bound
IgG may then be transcytosed to the basolateral side, where
it is released upon exposure to neutral pH (7.4). The FcRn
molecule may then be recycled to the maternal membrane
to perform additional rounds of transcytosis, as observed in
other systems [27]. Therefore, pH-dependent binding of IgG
to FcRn allows for IgG transport through a cell layer and
down a concentration gradient of IgG [28–30]( Figure 1).
Transcytosed IgG may or may not pass through the
stroma before reaching the fetal blood vessels. It remains
controversial as to whether FcRn is also expressed in the
fetal vessel endothelium, where greater evidence exists for
the action of alternative Fc receptors in further movement of
IgG [31, 32]. This IgG transport model is supported by the
in situ localization of IgG and FcRn subunits and by studies
investigating IgG transport in ex vivo perfused placentae
[33]. The FcRn α-chain has been found to be localized
mainly in intracellular vesicles and to a minor extent at the
apicalmembraneofSTBofﬁrsttrimesterandtermplacentae
[26, 33, 34].
The function of FcRn also extends to many other sites
withinthebody,whereitplaysanimportantroleinmodulat-
ing lifelong humoral and cell-mediated immune responses.
It is also expressed in both endothelial and bone marrow-
derived cells and plays an integral role in protecting IgG
from catabolism, which allows IgG to be recycled to the cell
surface and back into the bloodstream, extending its half-
life in the serum of adults [35]. FcRn is also expressed in
manyothertissuesintheadultanimal,includingbarriersites
such as the blood-brain interface, the glomerular ﬁlter in
the kidneys and the intestinal epithelium, where its function
of modulating IgG transport to promote host defense or to
control immune-complex deposition is still speculative [36].
To be transferred through human placenta, maternal IgG
mustcrosstheSTBs,thestromaoftheintravillousspace,and
the fetal vessel endothelium. These tissues express unique
patterns of various types of Fc receptors of IgG including
FcγRI, FcγRII, and FcγRIII. In the placenta, FcγRI has been
found in the loose connective tissue, mononuclear phago-
cytes, and the Hofbauer cells, which are morphologically de-
ﬁned as macrophages due to their ability to perform phago-
cytosis and to interact with IgG. Trophoblast cells in term
placentae express both FcγRIII and FcRn. Placental FcγRIII
is a membrane-spanning FcγRIIIa isoform, which is pre-
dominantlyexpressedbyNaturalKiller(NK)cells.Thebind-
ing of FcγRIII (also called CD16) on NK cells to immune
complexes or IgG on target cells, or treatment with an anti-
CD16 monoclonal antibody to crosslink membrane span-
ningFcγRIIIinducesNKcellactivation.Thisactivationleads
to upregulation of the transcripts for cytokines such as IFN-
γ and TNF-α [37, 38]. These observations indicate that
FcγRIIIa on trophoblasts may bind immune complexes or
antibody-coated particles in the maternal circulation and
may induce the transcription of cytokines or trigger cell-
mediated immunity.
Fetal endothelial cells in placenta express FcγRII and
FcRn although data regarding FcRn expression in the endo-
thelium are still conﬂicting [39].
3. Placental Transport of IgG Depends on
Maternal Levels
The newborn IgG antibodies’ levels usually correlate with
maternal ones (Figure 2); however, the IgG binding to
FcRn receptor can be saturated. Thus, the amount of IgG
transmitted depends on the amount of cell surface receptors,
because unbound IgG molecules are digested by lysosomal
enzymes inside the vesicles [40]. This has been reported in
several works performed in certain regions of Africa showing
lower cord/maternal placental transfer ratios of total IgG,
indicating that this limitation of active placental transfer
of antibodies is related to the higher maternal IgG levels
c o m m o ni nA f r i c a[ 41–43]. It was reported by Michaux et
al. [44] that total IgG concentrations in cord sera tend to be
lower than in their mothers when total IgG levels in maternal
serum reached 15g/L. This is in agreement with other works
that have demonstrated signiﬁcant negative correlations
between maternal levels of IgG and placental transfer ratios4 Clinical and Developmental Immunology
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Figure 2:CorrelationindexesandplacentaltransferratiosofmaternalandtermcordbloodIgGlevelsreactivewithtetanustoxoid,O111LPS
from enteropathogenic E. coli and Hib polysaccharide. Correlation indexes and placental transfer is higher to thymus-dependent antigens,
as tetanus toxoid than to thymus-independent antigens type I and II, as LPS and polysaccharides, respectively.
to the neonate for both total IgG and, interestingly, IgG
speciﬁc to measles, LPS and other antigens [41, 45, 46].
Sincethe1970s,M¨ antyj¨ arvietal.[47]havedemonstrated
that neonatal anti-inﬂuenza A2 IgG levels on average tends
to exceed that of the mother if the maternal level is low or
normal. When the mother has a high content of total IgG or
of a speciﬁc antibody, the neonatal value usually remained
below the maternal one. This inverse relationship between
the eﬃciency of placental transfer to the respective maternal
level was also demonstrated for herpes simplex virus, tetanus
toxoid, streptolysin O, and S. pneumoniae [48]. This is an
interesting observation, because it is known that placental
transport is mediated by the interaction between the Fc
portion of IgG and the FcRn receptor, in which the Fab
portion of this immunoglobulin is not involved. However,
this phenomenon suggests an involvement of antigenic spec-
iﬁcity of the antibody for this transport, but further studies
are needed to investigate the mechanism involved.
4.IgGTransportDepends on the Subclass
It is not clear why some antibody speciﬁcities exhibit differ-
enttransferimpairmentsindiﬀerentstudies[49].Aplausible
explanationmaylieinvariationintheIgGsubclassresponses
to diﬀerent antigens and the diﬀerent aﬃnities of these
subclasses to the IgG-transporting FcRn receptors [50, 51].
Preferential transport occurs for IgG1, followed by IgG4,
IgG3,andIgG2,forwhichtheFcRnreceptorshavethelowest
aﬃnity [52]( Figure 3). This has been clearly demonstrated
in studies on the transfer pattern of diﬀerent types of speciﬁc
IgG antibodies showing peculiarities in this transmission.
IgG1 and IgG3 are transferred more eﬃciently across the
placenta than IgG2. Furthermore, the transfer of antibodies
against viral proteins and antitoxins of the IgG1 subclass
occurs more readily. However, antibodies against encapsu-
lated bacteria (Haemophilus inﬂuenzae, Neisseria meningi-
tidis, and Streptococcus pneumoniae) in which IgG2 prevails,
at least after natural exposure, are transferred less eﬃciently
[53, 54], and an eﬀective transplacental transmission of IgG
antibodies reactive with LPS involving the IgG1 and IgG2
subclasses was conﬁrmed in our previous studies [55].
In addition, it has been demonstrated that in term neo-
nates with a low birth weight, all IgG subclasses were trans-
ferred with reduced eﬃciency, but IgG1 and IgG2 subclasses
were transferred with signiﬁcantly less eﬃciency than IgG3
and IgG4. These results demonstrate that low birth weight is
associated with impaired placental transfer of IgG1 and IgG2
subclasses.
Overall,atterm,IgGincordbloodhasagoodcorrelation
with maternal levels, and placental transfer is systematically
higher to thymus-dependent antigens (proteins), as tetanus
toxoidthantothymus-independentantigens,bothtypeIand
II, as LPS and polysaccharides, respectively [56]( Figure 2).
5.IgGTransport Dependson GestationalAge
IgG transfer from mother to fetus begins as early as 13 weeks
of gestation, and transport happens in a linear fashion as the
pregnancy progresses, with the largest amount transferred
in the third trimester [39]. Malek and colleagues [57]d e m -
onstrated a continuous rise in IgG levels in the fetal cir-
culation between 17 and 41 weeks of gestation. Fetal IgG
concentrations were only 5%–10% of the maternal levels at
weeks17–22butreached50%ofthematernalconcentrations
at weeks 28–32. The majority of IgG is acquired by the
fetus during the last 4 weeks of pregnancy, and fetal IgG
concentrations usually exceed maternal ones by 20%–30% at
full term [39]. Interestingly, a sharp increase in cord blood
levels occurs after the 36th week of gestation.
At term, dependent on the immunological experience of
the mother, placental transfer allows the newborn to acquire
diﬀerent speciﬁcities of IgG antibodies, resulting in an iden-
tical recognition pattern of antigens between the mother
and her oﬀspring. As shown in Figure 4, an immunoblotting
assay demonstrates identical patterns of enterohemorrhagic
E. coli (EHEC) antigen recognition between paired motherClinical and Developmental Immunology 5
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Figure 4: Immunoblotting of anti-EHEC O157:H7 IgG antibodies
in the paired maternal and cord samples. Bacterial proteins were
separated by 12.5% SDS-PAGE. Paired maternal and cord serum
samples are identiﬁed numerically. M: maternal serum; C: cord
serum; NHS: pool of healthy adult serum samples (normal human
serum). The immunoblots were developed with antihuman IgG
conjugate. Molecular weight standards are on the left for samples
1–8 and on the right for the pool of normal human serum. It was
observedthatthereisalmostcompleteidentitybetweentheantigens
recognized by maternal and umbilical cord sera [58].
and term cord sera, thus conﬁrming abundant transfer of the
maternal antibody repertoire to the newborn at least for pro-
tein antigens.
Maternal age, weight, parity, and type of delivery do not
inﬂuence placental antibody transfer [59].
Total IgG concentrations in newborns, therefore, are
directly related to length of gestation, and infants born at
less than 33 weeks of gestation have substantially lower IgG
levels than full-term babies (Figure 5). As the expression of
FcRn receptor is dependent on gestational age and seems to
be more highly expressed in the third trimester of human
pregnancy, a reduced placental transfer of antibodies is
observed at early stages of gestation. This fact results in
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Figure 5: Total IgG concentrations in cord serum samples from
newborns in diﬀerent gestational weeks [46, 60]. ∗Number of
samples in each period.
a reduced transfer of IgG subclasses, especially IgG1 and
IgG2, in preterm compared with full-term babies [56].
Accordingly, in a recent study, van den Berg et al.
[54] found signiﬁcantly lower transplacental transmission
of IgG in preterm infants (<32 weeks) than in full-term
infants for antibodies against diphtheria, tetanus, pertussis,
Haemophilus inﬂuenza type b (Hib), and Neisseria menin-
gitides serogroup C. In agreement with these data, Silveira
Lessa et al. [46] evaluated the placental transfer ratios of IgG
antibodies reactive with Klebsiella, Pseudomonas, and E. coli
O111, O26, and O6 lipopolysaccharides and showed lower
anti-LPS IgG transfer ratios in preterm groups (<33 weeks
and >33 weeks) as compared with term ones (>37 weeks).6 Clinical and Developmental Immunology
6. The Inﬂuence of MaternalImmunization
AmainfocusofthestudyofIgGtransportacrosstheplacenta
is maternal vaccination. Currently, several routine vaccines
are recommended for pregnant women, such as tetanus tox-
oid vaccine and inactivated inﬂuenza virus vaccine. Others
are used in special circumstances, including polysaccharide
vaccines, such as pneumococcal polysaccharide vaccine and
meningococcal polysaccharide vaccine, and inactivated viral
vaccines, such as hepatitis A and B, rabies virus, or inac-
tivated poliovirus vaccines [61]. All of these vaccines are
given to protect women from serious diseases during preg-
nancy and the postpartum period while potentially provid-
ing beneﬁts to the fetus and neonate due to placental trans-
mission of those maternal antibodies.
However, many factors may limit the placental transfer
eﬃcacy after maternal vaccination, such as the timing be-
tween immunization at the pregnancy and delivery, the ges-
tational ageof the fetus at birth, total maternal IgG levels and
thematernalvaccine-speciﬁcIgGandIgGsubclassesconcen-
trations [62, 63].
Several randomized studies have been conducted aiming
to study the eﬀectiveness of maternal vaccination, targeting
importantpathogensinearlychildhood[64,65].Prospective
studies have demonstrated higher cord antibody levels to
inﬂuenza in babies born to mothers immunized during
pregnancy [66]. Infants of vaccinated mothers were 45%–
48% less likely to have inﬂuenza hospitalizations than infants
of unvaccinated mothers [67]. Maternal inﬂuenza vaccina-
tion eﬀectiveness for both mother and newborn was also
demonstrated in developing countries [68, 69].
Recently, it was showed that Tdap (tetanus and diphthe-
ria toxoids and acellular pertussis antigens) vaccination in
pregnancywassafeandsigniﬁcantlyincreasedantibodytiters
against those antigens. These data reinforced that maternal
Tdap vaccination in the second trimester may prevent neo-
natal pertussis disease in the ﬁrst 5-6 months of life until
infants receive active vaccinations with Tdap at 2, 4, and 6
months of age and establish active immunity [70].
In clinical studies, several factors can aﬀect the transport
of antibodies speciﬁc to vaccine antigens, particularly the
type of vaccine administered. Vaccines with the ability to
induce higher maternal levels of IgG and speciﬁcally IgG1,
such as Hib polysaccharide- (PRP-) conjugate vaccines result
in increased concentrations of IgG1 delivered to the fetus
[61] and signiﬁcantly more PRP-speciﬁc IgG antibodies dur-
ing at least the ﬁrst 2 months of life in diverse populations
[71–75]. The same was observed for type III capsular pol-
ysaccharide of Group B Streptococcus (GBS) conjugated to
tetanus toxoid vaccine, demonstrating an eﬃcient transport
of GBS-speciﬁc IgG antibodies to the neonate [76].
Reports on maternal-fetal transfer of antibodies against
the capsular polysaccharides of S. pneumoniae have demon-
stratedthateventerminfantsgenerallyreceiveonlyafraction
(50%–85%) of either naturally acquired [77]o rp o l y s a c -
charide vaccine-induced antibodies from their mothers [63,
78–82]. Although higher IgG antibody levels are found in
oﬀspring of immunized compared to unimmunized women,
these titers are not maintained for a long time after birth,
they likely increase protection from invasive pneumococcal
disease until around 120 days after birth, when disease rates
are very high [78]. In contrast to the polysaccharide vaccine,
maternal immunization schedules including a conjugate
pneumococcal vaccine have the potential advantage of stim-
ulatingalargerquantityofantibodiesoftheIgG1ratherthan
the IgG2 subclass [83].
Another point that merits discussion is that higher
dosesofpassivelyacquiredantibodiesmaysuppressantibody
responses to active immunization in early infancy. Several
studies have also reported that maternal antibodies can in-
hibit infant responses to measles, tetanus, whole cell pertus-
sis, and Hib vaccines; this eﬀect varies considerably between
diﬀerent vaccines and studies [84–87]. Regarding toxoids,
it was observed that infants who had considerable levels of
pre-existing antibodies exhibited lower responses after active
immunizationtodiphtheriatoxoidaftertheseconddose,but
after 12 months of life, antibody titers do not diﬀer between
thoseinfantswhosemothershadlowtiters.Fortheconjugate
PRP-T vaccine, the anti-Hib antibody response was not
aﬀected by high maternal antitoxin titers; however, the in-
fants’ response to tetanus toxoid was dampened by these
high titers. Despite this, all infants achieved protective levels
of tetanus antitoxin-IgG after the booster dose with PRP-T.
Regarding polysaccharide vaccines, studies have shown no
diﬀerence in immune response of infants whose mothers
received the vaccine or not during pregnancy when they are
given the doses at 6–8 months of life. This observation was
made with both meningococcal polysaccharide and Hib vac-
cines [88].
The mechanisms through which maternal antibodies
inhibit infant responses to vaccination are not fully under-
stood. However, some plausible explanations are as follows:
(i) neutralization of live viral vaccines, (ii) vaccine antigen
immune complexes inhibiting infant B cell activation medi-
ated by FcγRIIb receptor, (iii) eﬀective elimination of vac-
cine antigen coated with maternal IgG antibodies via Fc-
dependent phagocytosis, and (iv) vaccine antigenic epitopes
being masked or hidden by maternal antibodies, preventing
binding by infant B cells [84, 89]. Although persistence of
maternal antibodies may limit infant antibody responses,
induction of T-cell responses remain largely unaﬀected by
these passively transferred antibodies, because the adminis-
tration of repeated vaccine doses, as routinely performed for
diphtheria-tetanus-pertussis-polio and Hib vaccines, is often
suﬃcient to overcome inhibition by maternal antibodies
[90].
7. Placental Transport of IgG in Infectious
Diseases
It is well known that antibody transport during pregnancy
can be aﬀected by a number of factors and clinical condi-
tions, including placental abnormalities, total IgG concen-
tration in maternal blood, the gestational age of the fetus at
birth, and maternal pathologies, such as hypergammaglob-
ulinemia, HIV infection, and placental malaria [91–93]. In
addition,pretermlaborsandintrauterinegrowthretardationClinical and Developmental Immunology 7
are associated with a number of pathologies, such as chronic
hypertensive disease or hypertensive disease during preg-
nancy, preeclampsia, gestational diabetes, and infections
whose inﬂuence in maternal antibody levels is still unknown
[94].
In cases of maternal HIV infection or placental injuries,
like malaria, a great decrease in antibody transfer has been
reported [48, 75, 95–97]. A multivariate regression analysis
study determined that placental malaria or maternal HIV
infection, independent of maternal hypergammaglobuline-
mia, are conditions that aﬀect placental transfer of anti-
bodies, and if the mother also has high IgG serum levels,
placental transfer is even more impaired [92].
It has been recently demonstrated that HIV-exposed but
uninfected infants have reduced transplacental transfer of
Hib-, pertussis-, pneumococcus-, and tetanus-speciﬁc anti-
bodies than their non-HIV exposed peers. These ﬁndings
wereconsistentwithtwootherstudiesinHIV-infectedwom-
en from Kenya, indicating that maternal HIV is associated
with lower tetanus and measles-speciﬁc antibodies in cord
blood and also with reduced placental antibody transfer
[98, 99]. However, although prenatal HIV exposure was
associated with lower speciﬁc antibody levels in exposed
uninfected infants compared with unexposed infants at
birth, after 16 weeks of life, robust and signiﬁcantly higher
antibodyresponsestopertussisandpneumococcusfollowing
routine vaccination were observed in the group of exposed
uninfected infants compared with control infants. Therefore,
HIV exposure is associated with a greater change in antibody
levels between birth and 16 weeks [100].
8. Placental Transfer inMothers with
PrimaryImmunodeﬁciencies
Women with humoral deﬁciencies are dependent on exoge-
nous administration of lgG to prevent recurrent infections
with possible severe morbidity and even mortality. In ad-
dition, in the absence of the intravenous immunoglobulin
(IVIG) therapy, their fetuses may also have an increased risk
of infection during intrauterine life and during the ﬁrst few
monthsafterbirthbecauseofreducedtransplacentaltransfer
of immunoglobulins from those mothers to their oﬀspring
[101].
Common variable immunodeﬁciency (CVID) is not an
extremely rare disorder, and currently, many patients reach
childbearing age in reasonably good health and become
pregnant. CVID represents a heterogeneous group of immu-
nologic disorders, characterized by reduced serum immuno-
globulin levels and impaired antibody responses, with vari-
able T cell numbers and function [102]. Its genetic heteroge-
neity has been studied in the last few years, with the identi-
ﬁcation of underlying defects in the following genes: ICOS
(inducible costimulator), BAFF-R (B-cell-activating factor
receptor), TACI (transmembrane activator and calcium-
modulator and cyclophilin ligand interactor), CD19, and,
more recently, CD20 and CD81 deﬁciencies [103].
There are only a few reports on total immunoglobulin
placentaltransferinthosecases[104–106],butitwasrecently
shown that CVID mothers under IVIG therapy eﬃciently
transferred exogenous IgG through the placenta in similar
patterns as endogenous immunoglobulins, as demonstrated
bythefollowing:(i)cordbloodIgGlevelsintermbabieswere
evengreaterthaninthemothers,(ii)apreferentialtransferof
IgG1, IgG3 and IgG4 compared with IgG2, (iii) antiprotein
IgG antibody levels equivalent to or higher than maternal
ones in cord serum and good transfer of antipolysaccharide
IgG antibodies, and (iv) similar anti-S. pneumoniae avidity
indexes between mothers and their respective neonates
(Table 1)[ 107]. Thus, CVID patients must be informed
about the relevance of regular IVIG administration during
pregnancy not only for their own health but also for the
immunity of their immature oﬀspring.
9. Placental Transfer inMothers with
Autoimmune Diseases
There are circumstances in which placental transmission of
antibodies is detrimental to the neonate. Neonatal lupus
erythematosus (NLE) is a rare disease considered to be the
exemplary prototypic model of passively acquired systemic
autoimmune disease [108]. Maternal IgG autoantibodies
against Ro/SSA and/or La/SSB or, less commonly, to U1-
ribonucleoprotein (U1-RNP), are transported through the
placenta and harm the fetus by causing injury to the skin
(cutaneous rash). One of the strongest clinical associations
is the development of congenital heart block, which is most
often of third-degree severity in a structurally normal heart.
Thisabnormalityisanalarmingprospectfacing2%ofmoth-
ers with these autoantibodies [109]. The risk of having a
second baby with NLE among women who have already had
a baby with NLE increases to 15% [110].
Sera of patients with autoimmune disorders contain an
active idiotypic-anti-idiotypic network, which can also be
induced in experimental animals following immunization
with B-cell epitopes of autoantigens. It has been shown that
sera of pregnant women with anti-La/SSB autoantibodies
who carry a healthy baby have signiﬁcantly higher levels
of anti-idiotypic antibodies to anti-La/SSB, suggesting that
these may serve as protective antibodies for the development
of congenital heart block [111]. Therefore, the presence of
anti-idiotypic antibodies to autoantibodies against La/SSB
may protect the fetus by blocking pathogenic maternal
autoantibodies.
The transference of autoantibodies was also reported in
neonatal pemphigus, which is characterized as a rare tran-
sitory autoimmune blistering disease caused by transfer of
maternal IgG autoantibodies speciﬁc for desmoglein 3 to the
neonate when the mother is aﬀected with pemphigus [112].
This disease is clinically characterized by transient ﬂaccid
blisters and erosions on the skin and rarely the mucosa.
However, by 3 months, IgG antidesmoglein levels in the
neonate are within normal limits [113]. Transient neonatal
autoimmunediseaseshavealsobeenreportedformyasthenia
gravis and antiphospholipid syndrome, and recently, a case
was reported of a newborn with transient epidermolysis
bullosa acquisita, a chronic, autoimmune bullous dermatosis8 Clinical and Developmental Immunology
Table 1: Serum immunoglobulin levels, speciﬁc antibody concentrations and avidity indexes in the maternal and cord serum and
cord/maternal serum ratios for IgG antibodies from a mother with CVID.
Maternal Cord Placental Transfer ratio (%)
Total Immunoglobulin Concentrations
IgG (mg/dL) 473.0 912.0 190
IgM (mg/dL) <6.0 12.0 –
IgA (mg/dL) <3.0 <3.0 –
IgG1 (mg/dL) 362.0 752.0 210
IgG2 (mg/dL) 249.0 192.0 80
IgG3 (mg/dL) 10.0 20.0 200
IgG4 (mg/dL) 6.0 21.0 350
Speciﬁc IgG Antibodies Levels
IgG anti-tetanus toxoid (UI/mL) 1.6 3.1 190
IgG anti-Hib PRP∗ (mg/L) 3.8 3.7 100
IgG anti-PS§1 (mg/L)/avidity (M)+ 2.3/>3.0 2.6/>3.0 110
IgG anti-PS3 (mg/L)/avidity (M) 2.4/>3.0 2.8/>3.0 120
IgG anti-PS5 (mg/L)/avidity (M) 7.3/2.7 8.0/2.7 110
IgG anti-PS6 (mg/L)/avidity (M) 6.9/2.7 6.6/>3.0 100
IgG anti-PS9 (mg/L)/avidity (M) 4.4/2.9 4.7/>3.0 110
IgG anti-PS14 (mg/L)/avidity (M) 12.8/2.5 15.0/2.8 120
–IgM and IgA maternal/cord blood ratios were not performed;
∗PRP—polyribosyl–ribitolphosphate polymers;
§Anti-PS—Anti-Streptococcus pneumoniae polysaccharide;
+(M)—Avidity index in molarity.
duetothepassivetransferofmaternalautoantibodiesagainst
the noncollagenous terminus of the α chain of type VII
collagen [114–116].
In autoimmune diseases in which pathogenic or excess
IgG antibodies are the etiological agents, such as myasthenia
gravis, bullous pemphigoid, idiopathic thrombocytopenic
purpura (ITP), and systemic lupus erythematosus (SLE), it
is sometimes advantageous to reduce endogenous serum IgG
levels by interfering with FcRn function. One possible way
to interfere with the function of FcRn is to overload it with
“innocuous” IgG. As FcRn functions as the IgG homeostatic
receptor, the level of FcRn expression determines the serum
concentration of IgG. Administering large quantities of
exogenous IgG raises the serum concentration above this
equilibrium set point and saturates FcRn [117]. As a result,
theexcessIgG thatdoes not bind to FcRn entersthe degrada-
tive pathway. This results in a shortening of the serum
IgG half-life. High-dose IVIG treatment is thought to exert
an immunomodulatory eﬀect by numerous mechanisms,
including engagement of the inhibitory FcγRIIb receptor
[118] and by FcRn saturation [117].
In mouse models of bullous pemphigoid, ITP and auto-
immune arthritis, IVIG treatment results in the dilution of
pathogenic antibodies to levels beneath the disease-causing
threshold [30, 119, 120]. The fact that a therapeutic eﬀect
for IVIG is maintained in FcγRIIb-deﬁcient mice and is
attenuated in FcRn-deﬁcient mice is strong evidence that
an important mechanism of action of IVIG is its ability to
compromise FcRn function [30, 121]. This approach pro-
videsavaluabletooltopreventneonatalautoimmunedisease
by exploiting the saturation of FcRn by high doses of IVIG
[122–125].
Finally, one interesting point that has been well explored
in murine models but not yet in humans is that placental-
derived IgG antibodies exert long-life immunoregulatory
functions, including imprinting the fetal immune network
[126]. Thus, by crossing the placenta, maternal IgG, in ad-
dition to providing anti-infectious protection to the infant,
could have other active immunoregulatory long-term eﬀects.
This mechanism of transplacental antibodies transfer could
also be involved in the recognition of allergens and priming
of small populations of allergen-speciﬁc T cells in the
newborn during intrauterine life, which could represent a
normal stimulatory signal [127].
10. Conclusions and Perspectives
The maternal IgG antibody transfer varies as a result of
total and speciﬁc maternal IgG levels, IgG subclass (and
thus, the nature of antigen), gestational age, and placental
integrity.Knowledgeofthefeaturesofplacentaltransmission
of IgG antibodies is crucial to exploit and manipulate this
mechanismtobeneﬁtthenewborn.Theﬁndingthatmothers
respond well to vaccination and are able to transfer their
entire antibody repertoire to their infants is encouraging,
raising the possibility of providing protection until the time
when the infant is vaccinated. Overall, the employment of
IVIG therapy promises to be an area of active research with
applications in mothers with primary immunodeﬁcienciesClinical and Developmental Immunology 9
to promote maternal and newborn protection against infec-
tions and in the treatment of various antibody-mediated au-
toimmune diseases, modulating transfer of harmful autoan-
tibodies.
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